Author | Editta Baldini, MD

Articles

Epirubicin/Taxane Combinations in Breast Cancer: Experience From Several Italian Trials

May 01, 2001

Doxorubicin/paclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing